Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estech's AF (atrial fibrillation) ablation tools:

This article was originally published in Clinica

Executive Summary

The US FDA has given Estech 510(k) clearance to sell its Cobra line of products for the surgical treatment of atrial fibrillation (AF). The tools, which were also recently cleared for sale in Europe, comprise the Cobra Adhere radiofrequency ablation system and the Cobra bipolar pacing probe. The Adhere device is used to make lesions on the heart to block the electrical impulses that cause AF. The pacing probe provides a means for immediately evaluating the effectiveness of AF treatment procedures. According to the Danville, California firm, the Cobra technology is unique in that it uses an "intelligent temperature-based" system that provides both optimal and reproducible results by regulating the RF energy. "Other systems offered by AtriCure, Medtronic and Guidant do not have this advanced energy regulation technology," the company claimed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT056614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel